MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Lexicon Pharmaceuticals ROA Ratio 2011-2026 | LXRX
Annual ROA Ratio Lexicon Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.21 | -67.15 | -77.2 | -52.47 | -64.1 | -28.74 | 31.15 | -42.43 | -29.56 | -29.74 | -0.71 | -21.28 | -37.98 | -29.64 | -26.99 | -27.74 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.15 | -77.2 | -33.24 |
Quarterly ROA Ratio Lexicon Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.64 | -33.44 | -41.55 | -54.59 | -46.09 | -64.37 | -58.36 | -63.68 | -64.28 | -63.24 | -62.48 | -42.86 | -53.38 | -41.18 | -52.03 | -34.79 | 5.75 | -14.73 | -36.89 | -26.05 | -38.29 | -24.7 | -0.68 | 21.28 | 27.62 | -36.15 | -38.44 | -42.43 | -42.62 | -39.8 | -35.58 | -28.17 | -28.9 | -29.64 | -29.71 | -29.74 | -9.61 | -7.45 | -3.75 | -0.72 | -14.65 | -17.83 | -19.04 | -21.28 | -27.01 | -29.96 | -35.05 | -37.98 | -38.32 | -34.72 | -31.08 | -29.64 | -30.82 | -28.93 | -28.15 | -26.99 | -6.06 | -6.19 | -6.88 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.62 | -64.37 | -29.66 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-241.53 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-22.19 | - | 1.35 % | $ 17.8 M |  China |
 |
Dynavax Technologies Corporation
DVAX
|
2.77 | - | - | $ 2.02 B |  USA |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-41.16 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-142.36 | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
-8.47 | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-179.56 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 52.49 | 5.4 % | $ 4.72 B |  Schweiz |
 |
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B |  Britain |
 |
CureVac N.V.
CVAC
|
20.2 | - | - | $ 867 M | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40.14 | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
-0.8 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-35.12 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-109.04 | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-207.62 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-43.36 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 31.58 | 0.99 % | $ 2.1 B | USA |
 |
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-121.19 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
36.63 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-102.69 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-36.68 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-5.72 | $ 14.75 | 0.2 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.92 | 2.82 % | $ 4.81 M | Israel |
|
Forte Biosciences
FBRX
|
-83.81 | $ 17.79 | 1.31 % | $ 230 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
53.1 | $ 0.68 | 1.7 % | $ 31.1 M | Israel |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-119.89 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.51 | 0.53 % | $ 3.12 B | USA |